Vybion will use intranasal delivery of loaded exosomes for its lead gene therapy for Huntington’s Disease. Vybion  developed a novel vectorized intrabody (INT41) for Huntington’s disease, a devastating inherited orphan disease that results in the progressive loss of both motor and cognitive function.  INT41 is effective in both cell-based system and animal models.  

INT41 has Orphan Disease Designation from the FDA and a pre-IND meeting defined the basic elements of the IND enabling package.

INT41 binds to an epitope that is unavailable in the functional molecule, but appears in the toxic degradation fragment that accumulates in the nucleus, binds to DNA via the polyglutamine and alters gene expression detectable years before the onset of symptoms. INT41 stabilizes this fragment and facilitates its degradation.

Vybion, Inc.

Org chart

Teams

Offices